Literature DB >> 32721652

Risk-Based lung cancer screening: A systematic review.

Iakovos Toumazis1, Mehrad Bastani2, Summer S Han3, Sylvia K Plevritis4.   

Abstract

Lung cancer remains the leading cause of cancer related deaths worldwide. Lung cancer screening using low-dose computed tomography (LDCT) has been shown to reduce lung cancer specific mortality. In 2013, the United States Preventive Services Task Force (USPSTF) recommended annual lung cancer screening with LDCT for smokers aged between 55 years to 80 years, with at least 30 pack-years of smoking exposure that currently smoke or who have quit smoking within 15 years. Risk-based lung cancer screening is an alternative approach that defines screening eligibility based on the personal risk of individuals. Selection of individuals for lung cancer screening based on their personal lung cancer risk has been shown to improve the sensitivity and specificity associated with the eligibility criteria of the screening program as compared to the 2013 USPSTF criteria. Numerous risk prediction models have been developed to estimate the lung cancer risk of individuals incorporating sociodemographic, smoking, and clinical risk factors associated with lung cancer, including age, smoking history, sex, race/ethnicity, personal and family history of cancer, and history of emphysema and chronic obstructive pulmonary disease (COPD), among others. Some risk prediction models include biomarker information, such as germline mutations or protein-based biomarkers as independent risk predictors, in addition to clinical, smoking, and sociodemographic risk factors. While, the majority of lung cancer risk prediction models are suitable for selecting high-risk individuals for lung cancer screening, some risk models have been developed to predict the probability of malignancy of screen-detected solidary pulmonary nodules or to optimize the screening frequency of eligible individuals by incorporating past screening findings. In this systematic review, we provide an overview of existing risk prediction models and their applications to lung cancer screening. We discuss potential strengths and limitations of lung cancer screening using risk prediction models and future research directions.
Copyright © 2020. Published by Elsevier B.V.

Entities:  

Keywords:  Computed tomography; Early diagnosis; Lung neoplasms; Pulmonary nodules; Risk assessment; Risk prediction; Screening; Statistical model

Mesh:

Year:  2020        PMID: 32721652     DOI: 10.1016/j.lungcan.2020.07.007

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  21 in total

1.  Blood-Based Biomarker Panel for Personalized Lung Cancer Risk Assessment.

Authors:  Johannes F Fahrmann; Tracey Marsh; Ehsan Irajizad; Nikul Patel; Eunice Murage; Jody Vykoukal; Jennifer B Dennison; Kim-Anh Do; Edwin Ostrin; Margaret R Spitz; Stephen Lam; Sanjay Shete; Rafael Meza; Martin C Tammemägi; Ziding Feng; Samir M Hanash
Journal:  J Clin Oncol       Date:  2022-01-07       Impact factor: 44.544

2.  A Novel M6A-Related Genes Signature Can Impact the Immune Status and Predict the Prognosis and Drug Sensitivity of Lung Adenocarcinoma.

Authors:  Xuewen Wang; Chengfei Zhao; Dandan Huang; Zhoujie Liu; Mengmeng Liu; Fei Lin; Yingyu Lu; Jing Jia; Liqing Lin; Xinhua Lin; Huangyuan Li; Zhiwei Chen
Journal:  Front Immunol       Date:  2022-07-04       Impact factor: 8.786

3.  Effectiveness of Perioperative Cardiopulmonary Rehabilitation in Patients With Lung Cancer Undergoing Video-Assisted Thoracic Surgery.

Authors:  Wei-Hao Chao; Sheng-Hui Tuan; En-Kuei Tang; Yi-Ju Tsai; Jing-Hui Chung; Guan-Bo Chen; Ko-Long Lin
Journal:  Front Med (Lausanne)       Date:  2022-06-15

Review 4.  Correlation between the Expression of VEGF and Ki67 and Lymph Node Metastasis in Non-small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.

Authors:  Dong Wei; Yunchao Xin; Yu Rong; Yanbing Hao
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-28       Impact factor: 2.650

Review 5.  Extracellular Vesicle Derived From Mesenchymal Stem Cells Have Bidirectional Effects on the Development of Lung Cancer.

Authors:  Jiayu Wang; Yiming Ma; Yingjiao Long; Yan Chen
Journal:  Front Oncol       Date:  2022-07-04       Impact factor: 5.738

6.  Screening human lung cancer with predictive models of serum magnetic resonance spectroscopy metabolomics.

Authors:  Tjada A Schult; Mara J Lauer; Yannick Berker; Marcella R Cardoso; Lindsey A Vandergrift; Piet Habbel; Johannes Nowak; Matthias Taupitz; Martin Aryee; Mari A Mino-Kenudson; David C Christiani; Leo L Cheng
Journal:  Proc Natl Acad Sci U S A       Date:  2021-12-21       Impact factor: 12.779

7.  A risk-based framework for assessing real-time lung cancer screening eligibility that incorporates life expectancy and past screening findings.

Authors:  Iakovos Toumazis; Oguzhan Alagoz; Ann Leung; Sylvia K Plevritis
Journal:  Cancer       Date:  2021-08-12       Impact factor: 6.860

8.  Deep Learning-Based Chest CT Image Features in Diagnosis of Lung Cancer.

Authors:  Jianxin Feng; Jun Jiang
Journal:  Comput Math Methods Med       Date:  2022-01-19       Impact factor: 2.238

9.  Lung cancer risk following previous abnormal chest radiographs: A 27-year follow-up study of a Chinese lung screening cohort.

Authors:  Yaguang Fan; Zheng Su; Mengna Wei; Hao Liang; Yong Jiang; Xuebing Li; Zhaowei Meng; Ying Wang; Heng Wu; Jinzhao Song; Youlin Qiao; Qinghua Zhou
Journal:  Thorac Cancer       Date:  2021-11-09       Impact factor: 3.500

10.  Functional Adhesion of Pectin Biopolymers to the Lung Visceral Pleura.

Authors:  Yifan Zheng; Aidan F Pierce; Willi L Wagner; Hassan A Khalil; Zi Chen; Andrew B Servais; Maximilian Ackermann; Steven J Mentzer
Journal:  Polymers (Basel)       Date:  2021-09-02       Impact factor: 4.329

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.